Abu Dhabi inks new production pact as UAE intensifies life sciences push

US healthcare group Abbott (NYSE: ABT) has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize pharmaceutical manufacturing, develop biosimilars, and accelerate digital transformation, as the emirate deepens its bid to become a regional powerhouse in the global life sciences sector.

Unveiled at the BIO International Convention in Boston, USA, the deal between Abbott and the Department of Health – Abu Dhabi also includes plans to digitize patient information materials and launch education programs aimed at cultivating local pharmaceutical talent. It forms part of a broader strategy to bolster healthcare self-sufficiency and position the UAE as an emerging hub for pharma and biotech innovation.

Mazen Bachir, regional director for Abbott’s established pharmaceuticals business, said the company will “focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment.” He added that the agreement also covers “digitising patient information leaflets and developing education programmes to support the development of local expertise.”